adapalene/minocycline (FCD105) / Yarrow Bioscience, Fortress - LARVOL DELTA

[VIRTUAL] A Prospective, Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination Of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne (FCDC 2020) - "Abstract not available."

Clinical • P2 data • Acne Vulgaris

VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) - "VYNE Therapeutics Inc...today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update...AMZEEQ (minocycline) topical foam, 4% for the treatment of inflammatory lesions of moderate to severe acne vulgaris in adults and patients 9 years of age and older continues to gain market share in acne. Prescription volume in Q3 2020 was 32,734, representing 52% growth from Q2 2020....End of Phase 2 meeting scheduled in Q4 for FCD105."

Commercial • FDA event • Acne Vulgaris • Dermatology

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam. (clinicaltrials.gov) - P2; N=446; Completed; Sponsor: Foamix Ltd.; Active, not recruiting ➔ Completed; Trial completion date: Jun 2020 ➔ Mar 2020

Clinical • Trial completion • Trial completion date • Acne Vulgaris • Dermatology • Dermatopathology

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam. (clinicaltrials.gov) - P2; N=446; Active, not recruiting; Sponsor: Foamix Ltd.; Trial primary completion date: May 2020 ➔ Feb 2020

Clinical • Trial primary completion date

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam. (clinicaltrials.gov) - P2; N=446; Active, not recruiting; Sponsor: Foamix Ltd.; Recruiting ➔ Active, not recruiting

Enrollment closed